Lenvatinib Plus Pembrolizumab vs Sunitinib in Advanced Renal Cell Carcinoma: Patterns of Progression and Subsequent Therapy in the CLEAR Trial

Panelists discuss how the evolving first-line treatment landscape for advanced renal cell carcinoma is shaped by novel immunotherapy combinations, including lenvatinib plus pembrolizumab, and the impact of these therapies on patient outcomes and progression patterns.

Panelists discuss how metastatic site–specific outcomes with first-line therapies for clear cell renal cell carcinoma (ccRCC) provide insights into the efficacy of treatment strategies based on the location of metastases.

Panelists discuss how clinical decision-making with TKI-IO combinations for advanced renal cell carcinoma involves evaluating factors such as efficacy, safety, patient characteristics, and the management of treatment-related toxicities to optimize patient outcomes.

Panelists discuss how the Phase phase 3 CLEAR trial evaluates organ-specific progression patterns in advanced renal cell carcinoma to better understand the efficacy of lenvatinib plus pembrolizumab compared to with sunitinib and guide subsequent treatment strategies.

Panelists discuss time to progression by organ with lenvatinib plus + pembrolizumab in advanced renal cell carcinoma (RCC), highlighting key data and its the implications for treatment decisions.

Panelists discuss the follow-up analysis of the CLEAR trial, examining its implications for clinical decision-making in the treatment of advanced renal cell carcinomaRCC.

Panelists discuss future directions in the treatment of advanced renal cell carcinoma (RCC), focusing on emerging therapies, clinical trials, and potential advancements in patient disease management.